Lohmann E, Thobois S, Lesage S, Broussolle E, du Montcel S Tezenas, Ribeiro M-J, Remy P, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y, Brice A
INSERM UMR S_679, Hôpital Pitié-Salpêtrière, Paris, France.
Neurology. 2009 Jan 13;72(2):110-6. doi: 10.1212/01.wnl.0000327098.86861.d4. Epub 2008 Nov 5.
To establish phenotype-genotype correlations in early-onset Parkinson disease (EOPD), we performed neurologic, neuropsychological, and psychiatric evaluations in a series of patients with and without parkin mutations.
Parkin (PARK2) gene mutations are the major cause of autosomal recessive parkinsonism. The usual clinical features are early-onset typical PD with a slow clinical course, an excellent response to low doses of levodopa, frequent treatment-induced dyskinesias, and the absence of dementia.
A total of 44 patients with EOPD (21 with and 23 without parkin mutations) and 9 unaffected single heterozygous carriers of parkin mutations underwent extensive clinical, neuropsychological, and psychiatric examinations.
The neurologic, neuropsychological, and psychiatric features were similar in all patients, except for significantly lower daily doses of dopaminergic treatment and greater delay in the development of levodopa-related fluctuations (p < 0.05) in parkin mutation carriers compared to noncarriers. There was no major difference between the two groups in terms of general cognitive efficiency. Psychiatric manifestations (depression) were more frequent in patients than in healthy single heterozygous parkin carriers but did not differ between the two groups of patients.
Carriers of parkin mutations are clinically indistinguishable from other patients with young-onset Parkinson disease (PD) on an individual basis. Severe generalized loss of dopaminergic neurons in the substantia nigra pars compacta in these patients is associated with an excellent response to low doses of dopa-equivalent and delayed fluctuations, but cognitive impairment and special behavioral or psychiatric symptoms were not more severe than in other patients with early-onset PD.
为了建立早发性帕金森病(EOPD)的表型-基因型相关性,我们对一系列有和没有帕金基因突变的患者进行了神经学、神经心理学和精神科评估。
帕金(PARK2)基因突变是常染色体隐性帕金森综合征的主要病因。其常见临床特征为早发性典型帕金森病,临床病程缓慢,对低剂量左旋多巴反应良好,频繁出现治疗引起的异动症,且无痴呆症状。
共44例早发性帕金森病患者(21例有帕金基因突变,23例无)以及9例未受影响的帕金基因突变单杂合携带者接受了全面的临床、神经心理学和精神科检查。
所有患者的神经学、神经心理学和精神科特征相似,但与非携带者相比,帕金基因突变携带者的多巴胺能治疗每日剂量显著更低,左旋多巴相关波动出现的延迟时间更长(p < 0.05)。两组在一般认知效率方面无显著差异。患者的精神科表现(抑郁)比健康的帕金基因突变单杂合携带者更常见,但两组患者之间无差异。
帕金基因突变携带者在临床上与其他年轻发病的帕金森病(PD)患者个体之间无法区分。这些患者黑质致密部多巴胺能神经元严重广泛丧失,与对低剂量多巴等效物反应良好及波动延迟有关,但认知障碍以及特殊行为或精神症状并不比其他早发性帕金森病患者更严重。